ERF:EURONEXT PARISEurofins Scientific SE Analysis

Eurofins Scientific is trading at €62.24, which sits just below its 20‑day (63.20), 50‑day (62.68) and 200‑day (63.19) simple moving averages, indicating a modest short‑term weakness. The RSI of 46 and a bearish MACD histogram (-0.18) reinforce a neutral‑to‑slightly bearish technical outlook, while the stock’s beta of 0.35 suggests limited market‑wide volatility, though 30‑day price swings remain elevated at ~22%.
Fundamentally, the company appears undervalued with a DCF‑derived fair value implying a ~14% upside and a forward P/E of 13.4 versus a trailing P/E of 24.4, outpacing the industry average. Revenue is growing at 4.3% YoY, earnings are projected to nearly double (trailing EPS €2.55 vs forward €4.65), and the dividend yield of 1.15% is backed by a modest payout ratio of 23.5% and solid free cash flow, despite a high debt‑to‑equity ratio of 96.8%.